Reata Pharmaceuticals, Inc. (RETA) EPS Estimated At $-0.66; Electro-sensors (ELSE) Shorts Decreased By 85.85%

April 17, 2018 - By Maria Brooks

Electro-Sensors, Inc. (NASDAQ:ELSE) Logo

Electro-sensors Inc (NASDAQ:ELSE) had a decrease of 85.85% in short interest. ELSE’s SI was 1,500 shares in April as released by FINRA. Its down 85.85% from 10,600 shares previously. With 17,100 avg volume, 0 days are for Electro-sensors Inc (NASDAQ:ELSE)’s short sellers to cover ELSE’s short positions. The SI to Electro-sensors Inc’s float is 0.09%. The stock increased 3.46% or $0.14 during the last trading session, reaching $4.19. About 3,657 shares traded. Electro-Sensors, Inc. (NASDAQ:ELSE) has declined 7.86% since April 17, 2017 and is downtrending. It has underperformed by 19.41% the S&P500.

Analysts expect Reata Pharmaceuticals, Inc. (NASDAQ:RETA) to report $-0.66 EPS on May, 10.They anticipate $0.34 EPS change or 106.25% from last quarter’s $-0.32 EPS. After having $-0.64 EPS previously, Reata Pharmaceuticals, Inc.’s analysts see 3.13% EPS growth. The stock increased 1.50% or $0.33 during the last trading session, reaching $22.3. About 128,670 shares traded. Reata Pharmaceuticals, Inc. (NASDAQ:RETA) has declined 19.56% since April 17, 2017 and is downtrending. It has underperformed by 31.11% the S&P500.

Electro-Sensors, Inc. manufactures and sells industrial production monitoring and process control systems. The company has market cap of $14.23 million. It offers various monitoring systems, which measure actual machine production and operation rates, as well as systems that regulate the speed of related machines in production processes. It has a 48.16 P/E ratio. The company's speed monitoring systems include a line of products that measure production counts or rates, such as parts, gallons, or board feet; and alarm systems, tachometers, and other devices that translate impulses from the sensors into alarm signals, computer inputs, or digital displays.

Investors sentiment increased to 3 in 2017 Q4. Its up 2.00, from 1 in 2017Q3. It increased, as 1 investors sold Electro-Sensors, Inc. shares while 0 reduced holdings. 2 funds opened positions while 1 raised stakes. 106,317 shares or 46.48% more from 72,583 shares in 2017Q3 were reported. Deutsche Bank & Trust Ag invested 0% of its portfolio in Electro-Sensors, Inc. (NASDAQ:ELSE). Royal State Bank Of Canada holds 16,538 shares or 0% of its portfolio. 1 are held by Wells Fargo & Mn. Renaissance Technology Ltd reported 83,700 shares. Blackrock Inc owns 222 shares.

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on identifying, developing, and commercializing product candidates for patients with rare and life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company has market cap of $583.26 million. The Company’s lead product candidates include Bardoxolone methyl, which is in Phase III clinical trial for the treatment of pulmonary arterial hypertension and associated with connective tissue disease, as well as in Phase II clinical trial for the treatment of pulmonary hypertension due to interstitial lung disease and pulmonary arterial hypertension; and Omaveloxolone that is in Phase II clinical trial for the treatment of Friedreich's ataxia, mitochondrial myopathies, and metastatic melanoma. It currently has negative earnings. The firm was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

Reata Pharmaceuticals, Inc. (NASDAQ:RETA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: